The interaction of maintenance interferon with cytolytic cells in patients with multiple myeloma who responded to cytotoxic chemotherapy

Pharmacotherapy

Volumn 17, Issue 2, 1997, Pages 248-255

  Hall, Philip D ^a   Self, Sally E ^a   Hall, Rayna Kneuper ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CD3 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IBUPROFEN; INTERLEUKIN 6; MELPHALAN; MITOXANTRONE; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HUMAN; KIDNEY FAILURE; MALE; MULTIPLE MYELOMA; NATURAL KILLER CELL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PROSPECTIVE STUDY; RELAPSE; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

AGED; ANTIGENS, CD3; ANTIGENS, CD56; ANTINEOPLASTIC AGENTS; BONE MARROW; HUMANS; IMMUNOPHENOTYPING; INTERFERON ALFA-2B; KILLER CELLS, NATURAL; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES;

EID: 0031000637     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with interferon alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990;332:1430-4.
2. Tribalto M. Maintenance treatment of multiple myeloma with recombinant alpha-2b interferon: an update after six years from the beginning of the Italian study. Haematologica 1991;76(suppl 4):50.
3. Salmon SE, Crowley JJ, Grogan TM, Finely P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a southwest oncology group study. J Clin Oncol 1994;12: 2405-14.
4. Peest D, Deicher H, Coldewey R, et al. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment in multiple myeloma. A prospective trial of the German myeloma treatment group. Eur J Cancer 1995;31A: 146-51.
5. Browman GP, Bergsagel D, Sicheri D, et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 1995;13:2354-60.
6. Westin J, Rodjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. Interferon alpha-2b versus no maintenance therapy during the plateau phase of multiple myeloma: a randomized study. Br J Haematol 1995;89:561-8.
7. Laszlo J, Huang AT, Brenckman WD, et al. Phase I study of pharmacological and immunological effects of human lymphoblastoid interferon given to patients with cancer. Cancer Res 1983;43:4458-66.
8. Edwards BS, Merritt JA, Fuhlbrigge RC, Borden EC. Low doses of interferon alpha result in more effective clinical natural killer cell activation. J Clin Invest 1985;75:1908-13.
9. Robertson MJ, Ritz J. Biology and clinical relevance of natural killer cells. Blood 1990;76:2421-38.
10. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression and human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986;136:4480-6.
11. LeFever AV, Funahasi A. Phenotype and function of natural killer cells in patients with bronchogenic carcinoma. Cancer Res 1991;51:5596-601.
12. Lotzova E, Savary CA. Generation of NK cell activity from human bone marrow. J Immunol 1987;139:279-84.
13. Sorskaar D, Forre O, Tjonneland S, Lie SO. Altered natural killer cell activity in childhood acute non-lymphoid leukaemia: augmented natural killer cell activity and cells expressing the Leu 7 and Leu 11b (CD16) markers in the bone marrow of children in remission. Scand J Immunol 1988;28:11-17.
14. Bataille R, Jourdan M, Zhang X-G, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84:2008-11.
15. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991;77:2794-5.
16. Reibnegger G, Krainer M, Herold M, Ludwig H, Wachter H, Huber H. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 1991;51:6250-3.
17. Jourdan M, Zhang X-G, Portier M, Boiron J-M, Bataille R, Klein B. IFN-α induces autocrine production of IL-6 in myeloma cell lines. J Immunol 1991;147:4402-7.
18. Blade J, Lopez-Guillermo A, Tassies D, Montserrat E, Rozman C. Development of aggressive plasma cell leukaemia under interferon-alpha therapy. Br J Haematol 1991;79:523-5.
19. Boldt DH, Mills BJ, Gemlo BT, et al. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Res 1988;48:4409-16.
20. Hall PD, Benko H, Hogan KR, Stuart RK. The influence of serum tumor necrosis factor-α and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol 1995;23:1256-60.
21. Bianchi A, Omede P, Attisano C, et al. Phenotypic and functional analysis of peripheral blood lymphocytes during interferon-alpha2b therapy in multiple myeloma patients with low tumor mass. Haematologica 1991;76:383-8.
22. Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol 1983;131:1789-96.
23. Abo T, Miller CA, Balch CM. Characterization of human granular lymphocyte subpopulations expressing HNK-1 (Leu-7) and Leu-11 antigens in the blood and lymphoid tissues from fetuses, neonates, and adults. Eur J Immunol 1984;14:616-23.
24. Uchida A, Yagita M, Sugiyama H, Hoshino T, Moore M. Strong natural killer (NK) cell activity in bone marrow of myeloma patients: accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells. Int J Cancer 1984;34:375-81.
25. Einhorn S, Ahre A, Blomgren H, Johansson B, Mellstedt H, Strander H. Interferon and natural killer cell activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer cell activity and clinical response to human interferon-α. Int J Cancer 1982;30:167-72.
26. Kay NE, Oken MM, Kyle R, et al. Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells. Leukemia Lymphoma 1995;16:351-4.
27. Sewell HF, Halbert CF, Robins RA, Galvin A, Chan S, Blamey RW. Chemotherapy-induced differential changes in lymphocyte subsets and natural-killer-cell function in patients with advanced breast cancer. Int J Cancer 1993;55:735-8.